Limited Impact of Passive Non-Neutralizing Antibody Immunization in Acute SIV Infection on Viremia Control in Rhesus Macaques

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Nakane, Taku ^a,b   Nomura, Takushi ^a,b   Shi, Shoi ^a,b   Nakamura, Midori ^a,b   Naruse, Taeko K ^c   Kimura, Akinori ^c   Matano, Tetsuro ^a,b   Yamamoto, Hiroyuki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELL MEDIATED VIRUS INHIBITION ASSAY; ARTICLE; CONTROLLED STUDY; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIREMIA; VIRION; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION, PASSIVE; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84883648509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073453     Document Type: Article

References (38)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. doi:10.1056/NEJMoa1113425. PubMed: 22475592.
3. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. doi:10.1038/nature11519. PubMed: 22960785.
4. Asmal M, Sun Y, Lane S, Yeh W, Schmidt SD, et al. (2011) Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol 85: 5465-5475. doi:10.1128/JVI.00313-11. PubMed: 21450829.
5. Forthal DN, Landucci G, Daar ES, (2001) Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75: 6953-6961. doi:10.1128/JVI.75.15.6953-6961.2001. PubMed: 11435575.
6. Forthal DN, Landucci G, Keenan B, (2001) Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retrovir 17: 553-561. doi:10.1089/08892220151126661. PubMed: 11350669.
7. Holl V, Hemmerter S, Burrer R, Schmidt S, Bohbot A, et al. (2004) Involvement of Fc gamma R I (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 173: 6274-6283. PubMed: 15528366.
8. Holl V, Peressin M, Schmidt S, Decoville T, Zolla-Pazner S, et al. (2006) Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107: 4466-4474. doi:10.1182/blood-2005-08-3490. PubMed: 16469871.
9. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, et al. (2006) Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 80: 6177-6181. doi:10.1128/JVI.02625-05. PubMed: 16731957.
10. Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104. doi:10.1038/nature06106. PubMed: 17805298.
11. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, et al. (2008) Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83: 791-801. PubMed: 18971271.
12. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182: 3718-3727. doi:10.4049/jimmunol.0803115. PubMed: 19265150.
13. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, et al. (2010) Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84: 7161-7173. doi:10.1128/JVI.00410-10. PubMed: 20444898.
14. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93. doi:10.1038/nature10766. PubMed: 22217938.
15. Florese RH, van Rompay KKA, Aldrich K, Forthal DN, Landucci G, et al. (2006) Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 177: 4028-4036. PubMed: 16951366.
16. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, et al. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108: 11181-11186. doi:10.1073/pnas.1103012108. PubMed: 21690411.
17. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, et al. (1996) Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett 51: 107-114. doi:10.1016/0165-2478(96)02563-1. PubMed: 8811353.
18. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018. PubMed: 10196297.
19. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, et al. (2003) Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 100: 15131-15136. doi:10.1073/pnas.2436476100. PubMed: 14627745.
20. Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T, (2007) Post-infection immunodeficiency virus control by neutralizing antibodies. PLOS ONE 2: e540. doi:10.1371/journal.pone.0000540. PubMed: 17579714.
21. Yamamoto T, Iwamoto N, Yamamoto H, Tsukamoto T, Kuwano T, et al. (2009) Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. J Virol 83: 5514-5524. doi:10.1128/JVI.00145-09. PubMed: 19297503.
22. Kestler HW III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662. doi:10.1016/0092-8674(91)90097-I. PubMed: 2032289.
23. Akari H, Mori K, Terao K, Otani I, Fukasawa M, et al. (1996) In vitro immortalization of old world monkey T lymphocytes with herpesvirus Saimiri: its susceptibility to infection with simian immunodeficiency viruses. Virology 218: 382-388. doi:10.1006/viro.1996.0207. PubMed: 8610465.
24. Argüello JR, Little AM, Bohan E, Goldman JM, Marsh SG, et al. (1998) High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). Tissue Antigens 52: 57-66. doi:10.1111/j.1399-0039.1998.tb03024.x. PubMed: 9714475.
25. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, et al. (2004) Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199: 1709-1718. doi:10.1084/jem.20040432. PubMed: 15210746.
26. Tanaka-Takahashi Y, Yasunami M, Naruse T, Hinohara K, Matano T, et al. (2007) Reference strand-mediated conformation analysis-based typing of multiple alleles in the rhesus macaque MHC class I Mamu-A and Mamu-B loci. Electrophoresis 28: 918-924. doi:10.1002/elps.200600586. PubMed: 17309048.
27. Naruse TK, Chen Z, Yanagida R, Yamashita T, Saito Y, et al. (2010) Diversity of MHC class I genes in Burmese-origin rhesus macaques. Immunogenetics 62: 601-611. doi:10.1007/s00251-010-0462-z. PubMed: 20640416.
28. Nomura T, Yamamoto H, Shiino T, Takahashi N, Nakane T, et al. (2012) Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in Burmese rhesus macaques. J Virol 86: 6481-6490. doi:10.1128/JVI.07077-11. PubMed: 22491464.
29. Iwamoto N, Tsukamoto T, Kawada M, Takeda A, Yamamoto H, et al. (2010) Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers. AIDS 24: 2777-2787. doi:10.1097/QAD.0b013e3283402206. PubMed: 21045637.
30. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463. doi:10.1128/JVI.01708-08. PubMed: 18842730.
31. Schäfer F, Kewenig S, Stolte N, Stahl-Hennig C, Stallmach A, et al. (2002) Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 50: 608-614. doi:10.1136/gut.50.5.608. PubMed: 11950804.
32. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, et al. (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 108: 7505-7510. doi:10.1073/pnas.1016048108. PubMed: 21502492.
33. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540. doi:10.1128/JVI.75.12.5526-5540.2001. PubMed: 11356960.
34. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, et al. (2007) Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 81: 5024-5035. doi:10.1128/JVI.02444-06. PubMed: 17329327.
35. Hirsch VM, Santra S, Goldstein S, Plishka R, Buckler-White A, et al. (2004) Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol 78: 275-284. doi:10.1128/JVI.78.1.275-284.2004. PubMed: 14671109.
36. Bergthaler A, Flatz L, Verschoor A, Hegazy AN, Holdener M, et al. (2009) Impaired antibody response causes persistence of prototypic T cell-contained virus. PLOS Biol 7: e1000080. PubMed: 19355789.
37. Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, et al. (2004) Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 78: 5983-5995. doi:10.1128/JVI.78.11.5983-5995.2004. PubMed: 15140996.
38. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, et al. (2010) Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 16: 1117-1119. doi:10.1038/nm.2233. PubMed: 20890292.